Dr. Sophie Dobiasch
Junior Group Leader Personalized Radiooncology, Institute of Radiation Medicine (IRM)
Dr. Sophie Dobiasch
Junior Group Leader Personalized Radiooncology, Institute of Radiation Medicine (IRM)
Career
In August 2015, she started a career as a clinician scientist at the Department of Radiation Oncology, Klinikum rechts der Isar. Through various research funding programs, she established the basis of her research focus “Personalized RadioOncology of pancreatic cancer”, and set up a junior research group.
Thematically and methodologically, she could build on her experimental thesis in the field of targeted nanoparticles for improved imaging and therapy in pancreatic cancer at the European Pancreatic Cancer Center Heidelberg.
As a clinician scientist, she aims to combine clinical activities and scientific projects, develop novel ideas and concepts, and work on translation from the lab to the clinic, as well as clinical questions from the clinic in the lab. With these translational approaches, she is closely involved in SFB 1321, the German Consortium for Translational Cancer Research (DKTK), and the working group young DEGRO of the society of radiation oncology.
In addition, her profile is completed by intercultural competencies from several stays abroad in Japan, Great Britain, India, and Nepal.
Her research focuses on mechanisms of radioresistance of pancreatic cancer. The treatment of pancreatic cancer, one of the most aggressive and lethal human tumors, is still an unsolved health problem. The poor survival can be attributed to a high genetic heterogeneity leading to therapeutic resistance. Therefore, individualized high-precision radiation concepts in combination with cytotoxic agents, targeted therapies, or herbal substances are new therapeutic approaches for pancreatic cancer.
The major goal of the research is to overcome the radioresistance of pancreatic cancer and thereby pave the way to novel effective treatments and improve the clinical outcome of patients with pancreatic cancer.
Skills and Expertise
Pancreatic Cancer Tumor Mouse Models Translational Research Small Animal Imaging Small Animal High-Precision Irradiation
Professional Career
Junior Group Leader
Institute of Radiation Medicine (IRM), Helmholtz Munich
Clinician Scientist
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich (TUM)
Medical doctor (MD)
European Pancreatic Cancer Center Heidelberg, Heidelberg University Hospital
Medical School
Ruprecht-Karls University Heidelberg
Honors and Awards
Research grant, Helmholtz Munich
Research grant, Hans und Klementia Langmatz Stiftung
Award for 2nd best young investigator talk, 4th Conference on Small Animal Precision Image-Guided Radiotherapy
Research grant, Medical Faculty of the Technical University of Munich, KKF
Most important publications
2022 Nature Methods
2021 Radiother Oncol.
Impact of DNA repair and reactive oxygen species levels on radioresistance in pancreatic cancer.
2020 Mol Cell Proteomics
Private thoughts
My key vision is to improve the outcome of patients with pancreatic cancer. Within a framework of translational research, novel preclinical approaches target radioresistance by innovative irradiation concepts and combination treatments.
My key vision is to improve the outcome of patients with pancreatic cancer. Within a framework of translational research, novel preclinical approaches target radioresistance by innovative irradiation concepts and combination treatments.
Networks and Affiliations
DKTK German Cancer Consortium
Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University Munich (TUM)
Institute for Pathology, Technical University Munich (TUM)
Proteomics and Bioanalytic, Technical University Munich (TUM)
European Pancreas Center, Heidelberg University Hospital
Translational Cancer Research, University Medical Center Göttingen
